A surey of bioanalysis methods for antibody drugs

doi:10.12092/j.issn.1009-2501.2020.02.017

Abstract

Abstract: Antibody drugs have become the first choice for clinical treatment of many diseases due to their advantages of targeting, high specificity and low toxicity. However, the disposal mechanism in vivo has its particularity and complexity, which greatly increases the difficulty of biological detection. Therefore, to establish the sensitive, accurate and repeatable methods is urgent. This paper mainly focuses on the bioanalytical methods of this kind of drugs, introduces the characteristics and application of enzyme-linked immunosorbent assay, electrochemiluminescence, liquid chromatography-mass spectrometry, flow cytometry and some new techniques, in hope of providing a reference for the study of related drugs.

Key words: monoclonal antibody, bioanalytical methods, LC-MS/MS, flow cytometry

CLC Number:

R917

ZHENG Fengjia, JIA Zhijun, XIE Xinyao, HAN Min, DONG Lihou. A surey of bioanalysis methods for antibody drugs[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 227-232.

References

［1］Frese K, Eisenmann M, Ostendorp R, et al. An automated immunoassay for early specificity profiling of antibodies［J］. mAbs, 2013, 5(2):279-287.
［2］Puri A, Niewiarowski A, Arai Y, et al. Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects［J］. Brit J Clin Pharmacol, 2017,83(7):1405-1415.
［3］李雪, 史晶莹, 董雪, 等. 一种人抗PD-L1单抗的间接ELISA方法的建立［J］. 生物技术, 2017, 27(6):552-556.
［4］李萌, 于传飞, 王文波, 等. 抗体偶联药物抗HER2单抗-MCC-DMl质控方法的建立［J］. 药物分析杂志, 2016, 36(1):22-30.
［5］Soderstrom CI, Spriggs FP, Song W, et al. Comparison of four distinct detection platforms using multiple ligand binding assay formats［J］. J Immunol Methods, 2011, 371(1/2):106-113.
［6］夏明. ECLIA法检测血清促甲状腺激素受体抗体在自身免疫性甲状腺病中的诊断价值［J］. 中国医学工程, 2015, 23(1):160-162.
［7］Lowe J, Maia M, Wakshull E, et al. Development of a novel homogenous electrochemiluminescence assay for quantitation of ranibizumab in human serum［J］. J Pharm Biomed Anal, 2010, 52(5):680-686.
［8］Smeraglia J, Silva JP, Jones K. Improving the sensitivity and specificity of a bioanalytical assay for the measurement of certolizumab pegol［J］. Bioanalysis, 2017, 9(16):1217-1226.
［9］赵小平. 两种不同免疫检验方法检测乙型肝炎病毒感染血清学标志物的临床对比探讨［J］. 中外医学研究, 2019, 17(3):61-62.
［10］Teimouri A, Modarressi MH, Shojaee S, et al. Detection of toxoplasma-specific immunoglobulin G in human sera: performance comparison of in house Dot-ELISA with ECLIA and ELISA［J］. Euro J Clin Microbiol, 2018, 37(8):1421-1429.
［11］Sumathi S, Mohamed K, Rabih S, et al. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study［J］. Lancet Infect Dis, 2018,18(8):884-893.
［12］Peng X, Liu B, Li Y, et al. Development and Validation of LC-MS/MS Method for the Quantitation of Infliximab in Human Serum［J］. Chromatographia, 2015, 78(7):521-531.
［13］Iwamoto N, Shimada T, Terakado H, et al. Validated LC-MS/MS analysis of immune checkpoint inhibitor Nivolumab in human plasma using a Fab peptide-selective quantitation method: nano-surface and molecular-orientation limited (nSMOL) proteolysis［J］. J Chromatogr B, 2016, 1023-1024:9-16.
［14］黄怡, 李晓宇, 田芳, 等. 质谱方法实现抗体类药物糖链修饰的鉴定与定量研究［J］.中国生物工程杂志,2018,38(1):32-41.
［15］Li H, Ortiz R, Tran L, et al. General LC-MS/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies［J］. Anal Chem, 2012, 84(3):1267-1273.
［16］Furlong MT, Titsch C, Xu W, et al. An exploratory universal LC-MS/MS assay for bioanalysis of hinge region-stabilized human IgG4 mAbs in clinical studies［J］. Bioanalysis, 2014, 6(13):1747-1758.
［17］Kang L, Camacho RC, Li W, et al. Simultaneous catabolite identification and quantitation of large therapeutic protein at the intact level by immunoaffinity capture liquid chromatography-high-resolution mass spectrometry［J］. Anal Chem, 2017, 89(11):6065-6075.
［18］Law WS, Genin JC, Miess C, et al. Use of generic LC-MS/MS assays to characterize atypical PK profile of a biotherapeutic monoclonal antibody［J］. Bioanalysis, 2014,6(23):3225-3235.
［19］Wang SJ, Wu ST, Gokemeijer J, et al. Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies［J］. Anal Bioanal Chem, 2012, 402(3):1229-1239.
［20］Lanshoeft C, Cianférani, Sarah, et al. Generic hybrid ligand binding assay liquid chromatography high-resolution mass spectrometry-based workflow for multiplexed human immunoglobulin G1 quantification at the intact protein level: application to preclinical pharmacokinetic studies［J］. Anal Chem, 2017, 89(4):2628-2635.
［21］Kang L, Weng N, Jian W. LC-MS bioanalysis of intact proteins and peptides［J］. Biomed Chromatogr, 2020, 34(1):e4633.
［22］Yver A, Homery MC , Fuseau E, et al. Pharmacokinetics and safety of roledumab, a novel human recombinant monoclonal anti-RhD antibody with an optimized Fc for improved engagement of FCγRIII, in healthy volunteers［J］. Vox Sanguinis, 2012, 103(3):213-222.
［23］Zhao WB, Qiu CX, Shen Y, et al. In situ, quantitative bioanalysis of monomethyl auristatin E-conjugated antibody-drug conjugates by flow cytometry［J］. Euro J Pharmaceut Sci, 2018, 120:89-95.
［24］邓承莲, 邹佳, 欧伦, 等. 两种重组抗CD20人源化单克隆抗体定量分析方法的比较及其在药代动力学研究中的应用［J］. 分析化学, 2014, 42(3):337-342.
［25］Liu R, Hoffpauir B, Chilewski SD, et al. Accelerating regulated bioanalysis for biotherapeutics: case examples using a microfluidic ligand binding assay platform［J］. AAPS J, 2017, 19(1):82-91.
［26］Chilewski SD, Mora JR, Gleason C, et al. Addressing matrix effects in ligand-binding assays through the use of new reagents and technology［J］. Bioanalysis, 2014, 6(8):1059-1067.
［27］Williams K, Erickson R, Fischer SK. Overcoming disease-specific matrix effect in a clinical pharmacokinetic assay using a microfluidic immunoassay technology［J］. Bioanalysis, 2017,9(16):1207-1216.
［28］Roman J, Qiu J, Dornadula G, et al. Application of miniaturized immunoassays to discovery pharmacokinetic bioanalysis［J］. J Pharmacol Toxicol Methods, 2011, 63(3):227-235.
［29］Mora JR, Obenauer-kutner L, Patel VV. Application of the GyrolabTM platform to ligand-binding assays: a user's perspective.［J］. Bioanalysis,2010,2(10):1711-1715.
［30］马春梅, 刘莉. 基于Biacore T200 分析系统研究阿达木单抗生物学活性［J］. 世界临床药物, 2016, 37(5):308-313.
［31］Winzor DJ. Interpretation of results from the competitive Biacore procedure for characterizing immunochemical interactions in solution［J］. J Mol Recognit, 2018, 31(7):e2702.
［32］Alaedini A, Latov N. A surface plasmon resonance biosensor assay for measurement of anti-GM1 antibodies in neuropathy［J］. Neurology, 2001, 56(7):855-860.
［33］Schlichtiger A, Baier C, Yin MX, et al. Covalent attachment of functionalized cardiolipin on a biosensor gold surface allows repetitive measurements of anticardiolipin antibodies in serum［J］. Anal Bioanal Chem, 2013, 405(1):275-285.
［34］Gilbert M, Livingston R, Felberg J, et al. Multiplex single molecule counting technology used to generate interleukin 4, interleukin 6, and interleukin 10 reference limits［J］. Anal Biochem, 2016, 503:11-20.
［35］Fraser S, Dysinger M, Soderstrom C, et al. Active glucagon-like peptide 1 quantitation in human plasma: A comparison of multiple ligand binding assay platforms［J］. J Immunol Methods, 2014, 407:76-81.
［36］Fischer SK, Joyce A, Spengler M, et al. Emerging technologies to increase ligand binding assay sensitivity［J］. AAPS J, 2015, 17(1):93-101.

[1]	YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei. Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177.
[2]	LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
[3]	GAO Rong, MA Yazhong, ZHAO Haixia, WANG Zhaoyuan, ZHANG Weihong, YUAN Hailong. Bioequivalence of amlodipine besylate tablets in Chinese healthy subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 56-62.
[4]	CAI Mingmin, SHAO Jing, TANG Lu, SUN Qiuyue, DOU Ting, QIAN Wei, WANG Huiping. Bioequivalence study of buthlphthalide injection in Chinese healthy volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 70-76.
[5]	XU Guofang, ZHANG Sisen, LIU Ping, MEI Jiazhuan, LIU Weiwei, LIU Ya'ou, QI Qi. Population pharmacokinetics of capecitabine in Chinese breast cancer patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 552-559.
[6]	MA Hong, LIU Jingyuan, JIN Hao, CHEN Yong, WANG Bo, LIU Wanhui, SI Duanyun, XIA Yuanyuan. Quantification of ambrisentan in human plasma by LC-MS/MS and its pharmacokinetic application [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 382-388.
[7]	WANG Hui, CUI Chang, YANG Shuang, YAO An, WU Shuting, YANG Xiaoyan, YE Ling, ZOU Zhi, TANG Zhi, YANG Guoping, HUANG Jie, OUYANG Dongsheng. Bioequivalence of solifenacin succinate tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 299-304.
[8]	LIU Chang, DENG Kunhong, HUANG Jie, YANG Shuang, YANG Xiaoyan, XIANG Yuxia, HUANG Lu, ZHANG Zeyu, LIANG Wenzhong, LAN Jing, YANG Guoping. Bioequivalence of moxifloxacin hydrochloride tablets in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1393-1399.
[9]	HOU Liping, YAN Yuyang, LI Li, YANG Jianbo, OUYANG Dongsheng. Development of quantitative analysis methods of Rituximab and it's biosimilar in biological samples [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 98-104.
[10]	YANG Dandan, CHEN Jinliang, WU Jinlian, CHEN Jing, LOU Honggang, RUAN Zourong, JIANG Bo. Bioequivalence of norfloxacin tablets in Chinese Healthy volunteers under Fasting and Fed Condition [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1357-1362.
[11]	HU Chaoying, GAO Dan, GAO Linyan, WAN Yanfei, GAO Bei, LI Lin, ZHANG Lan. Bioequivalence study of cetirizine hydrochloride tablets under fasting and fed conditions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1363-1368.
[12]	Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, GCP Center Phase I Clinical Trial Ward, Shenyang , Liaonning, China. Bioequivalence of rosuvastatin calcium tablets in Chinese healthy subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1369-1375.
[13]	YANG Xinyi, ZHANG Jing, LI Nanyang, YANG Haijing, MAO Xiaomeng. New progress in drug prevention and treatment of migraine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1429-1435.
[14]	SUN Qing, SUN Jianfang, LI Li, CHANG Huichao, ZHOU Quan. Effects of Wuzhi capsule on the pharmacokinetics of simvastatin and its metabolite simvastatin acid in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(11): 1242-1249.
[15]	XING Han, NING Chen, KONG Dexuan, CAI Hui, ZHOU Shiyu, REN Chang, KONG Ying, CHENG Yujie, CHEN Xijing. Tissue distribution and excretion study of GL-V9 in rats, a wogonin derivative with significant antitumor activity [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 889-895.